HYPERFINE Defining the Future of Life-Saving Diagnostics at the Point of Care Corporate Presentation | March 23, 2022 © 2022 Hyperfine, Inc. Forward Looking Statements This presentation includes forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are f ...

Market Opportunity - The Swoop scanner targets a $15.9 billion global imaging market, expected to grow at a 5.2% CAGR from 2021 to 2028[22] - The global imaging market is projected to grow from $15.9 billion to over $20 billion, with significant opportunities for the Swoop scanner in underpenetrated markets[43] - The market for global non-invasive brain trauma monitoring devices is expected to grow from approximately $10.1 billion in 2019 to $18.3 billion by 2027, at a CAGR of 7.7%[48] Product Features and Benefits - The Swoop scanner reduces the conventional MRI workflow time from an average of 25.8 hours to 90 minutes, achieving a 94% reduction[32] - The Swoop scanner has the potential to increase the utilization of existing MRI suites by 20% through bedside imaging, allowing for more outpatient procedures[33] - The Swoop scanner is designed to provide immediate point-of-care brain imaging, particularly beneficial for critically ill patients who cannot be transported[31] - The Swoop scanner's lower price point makes it accessible for hospitals that cannot afford conventional MRI or CT scanners[31] - The Swoop scanner is designed to improve patient care by reducing the risk of injury during transport and minimizing anxiety related to imaging procedures[32] - The Swoop scanner is designed to facilitate early diagnosis and intervention, potentially leading to cost savings for patients, providers, and payors[37] - The Swoop portable MRI system delivers diagnostic quality images with a resolution of 1.5 mm x 1.5 mm x 5 mm, compared to conventional MRI's typical resolution of 1.0 mm x 1.0 mm x 5 mm, despite operating at a lower magnetic field strength of 0.064-Tesla[62] - The Swoop scanner can be powered by a standard wall outlet and uses less than 900W of electricity, eliminating the need for liquid helium and other complex infrastructure required by conventional MRI systems[71] Research and Development - The company is developing non-invasive brain sensing technology to monitor key brain vital signs, aiming to enhance patient care and expand its product offerings[41] - Approximately 30% of conventional MRI scans suffer from moderate to severe image quality issues due to patient motion, which the company aims to address with its newly developed motion compensation technology that has received FDA clearance for clinical use[57] - The company is investing $50 million in R&D for new technologies aimed at improving imaging capabilities[2] - Research and development investments increased by 10% to $150 million, focusing on innovative technologies in the utility sector[3] - Research and development investments increased by 30%, focusing on innovative medical imaging solutions[112] Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching $1.5 billion for the quarter[2] - The company reported a significant increase in revenue, achieving $1.5 billion in Q3 2023, representing a 25% year-over-year growth[2] - The company provided guidance for Q4 2023, projecting revenue between $1.6 billion and $1.8 billion, which reflects a growth rate of 20% to 30% compared to Q4 2022[4] - The company incurred net losses of $64.9 million and $23.4 million for the years ended December 31, 2021 and 2020, respectively, with an accumulated deficit of $136.3 million as of December 31, 2021[189] - The company may need to raise additional capital to fund commercialization plans for its products, including manufacturing, sales, and marketing activities[193] Regulatory and Compliance - The FDA requires pre-market review for medical devices, with significant user fees over $12,000 for 510(k) and $374,000 for PMA in FY 2022[130] - The company is subject to FDA inspections and must comply with Good Manufacturing Practice requirements, which include extensive quality management protocols[152] - The company must ensure compliance with evolving EU laws on data export, particularly following the invalidation of the EU-U.S. Privacy Shield[171] - The company faces potential fines of up to $100,000 per violation under the federal Anti-Kickback Statute, with imprisonment for up to ten years for serious violations[157] Strategic Initiatives - The company aims to expand its market presence in the UK, Australia, New Zealand, and Pakistan through strategic partnerships and grant funding[34] - The company plans to continue building its direct commercial infrastructure in the U.S. while exploring distributor partnerships for international sales[95] - The company is exploring partnerships with healthcare providers to expand its reach in the medical sector[112] Competitive Landscape - The competitive landscape includes established players like General Electric and Siemens, with significant barriers to entry for new entrants in the medical imaging market[103] - The company faces significant competition from established players in the medical imaging market, including General Electric, Siemens, and Philips[205] Corporate Governance and Sustainability - The company emphasizes environmental sustainability initiatives, including efforts to reduce its environmental footprint and increase energy efficiency[81] - The company is focused on enhancing its corporate governance practices and sustainability measures over time[88] - The company is committed to diversity, equity, and inclusion, focusing on building a diverse workforce to enhance innovation and performance[85]

Hyperfine, Inc. (NASDAQ:HYPR) Q4 2021 Earnings Conference Call March 23, 2022 4:30 PM ET Company Participants Dave Scott - President and Chief Executive Officer Alok Gupta - Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Anthony Petrone - Mizuho Group Operator Thank you, and thank you all for joining today’s call. Joining me are Dave Scott, President and Chief Executive Officer; and Alok Gupta, Chief Financial Officer of Hyperfine. Earlier today, Hyperfine released financial ...

HYPERFINE Defining the Future of Life-Saving Diagnostics at the Point of Care Corporate Presentation | January 2022 © 2022 Hyperfine, Inc. Forward Looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Hyperfine's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of fut ...

Table of Contents Commission file number: 001-39935 HEALTHCOR CATALIO ACQUISITION CORP. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Exact Name of Registrant as Specified in Its Charter) | Cayman Islands | 9 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39935 HEALTHCOR CATALIO ACQUISITION CORP. (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 98-1569027 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39935 HEALTHCOR CATALIO ACQUISITION CORP. (Exact Name of Registrant as Specified in Its Charter) | Cayman Islands | 98-15 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HealthCor Catalio Acquisition Corp. (Exact name of registrant as specified in its charter) | Cayman Islands | 001-39949 | 98-1569027 | | --- | --- | --- | | (State or other jurisdiction of | (Commission File Number) | (I.R.S. Employer Identification | | incorporation or organization) | | Numbe ...